FindTrial
Sign In

Study on the effect of drug metabolizing enzyme and transporter gene polymorphism on the pharmacokinetics of rivaroxaban

Study on the effect of drug metabolizing enzyme and transporter gene polymorphism on the pharmacokinetics of rivaroxaban

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092227
Enrollment
Unknown
Registered
2024-11-12
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of venous thromboembolism in adults undergoing selective knee or hip joint surgery intervention

Interventions

Rivaroxaban administration group:None

Sponsors

Huzhou Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The bioequivalence study of rivaroxaban tablets in healthy subjects was conducted in a randomized, open label, two dose, single dose, four cycle repeated crossover fasting and postprandial state (Ethics Approval No.: Lunshen No. (2020-014-02)) with 36 healthy subjects after a single oral dose of rivaroxaban tablets.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
Polymorphisms of Drug Metabolism Enzymes and Transporter Genes;Cmax;AUC0-t;AUC0-8;—

Countries

China

Contacts

Public ContactChen Yingrong

Huzhou Center Hospital

chenyingrong2006@163.com+86 572 2819601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026